The technology is exclusively licensed from Yale University and uses a cell-penetrating antibody to noncovalently bind to and deliver therapeutic levels of a wide variety of nucleic acid payloads to select cells. The nonviral delivery platform can deliver multiple types of nucleic acids, allows for repeat dosing, and is produced using well established manufacturing processes, according to the firm.

The series A financing was co-led by OrbiMed and Logos Capital, with participation by Surveyor Capital (a Citadel company).